drugset / Trial / NCT05765747

Effectiveness of Yunnan Baiyao in Improving Fracture Pain

NCT05765747

Unknown 58 enrolled Peking University Third Hospital
RandomizedParallel-groupOpen-labelTreatment

Summary

This will be a randomized, controlled, non-inferiority designed clinical trial. 56 qualified subjects will be selected and allocated 1:1 to Yunnan Baiyao group and celecoxib group. Each subject will be treated for 2 weeks and observed for 12 weeks, which will be lasted for 14 weeks during the whole trial. Yunnan Baiyao group will be given 4 times a day, 2 capsules each time after morning, afternoon and evening meals and before going to bed. One capsule of Baoxianzi will be provided for the first time to be taken at the same time with Yunnan Baiyao Capsule, which will be given continuously for 2 weeks. The celecoxib group will be given 1 capsule twice a day after breakfast and dinner for 2 weeks.

Timeline

Start
2023-04-01
Primary completion
2023-12-31
Completion
2024-06-01

Drugs

EvaluationDrugModalityDoseRoute
Comparator Celecoxib Other / unclassified 200 mg
Subject Yunnan Baiyao Traditional medicine (herbal / TCM)
Background Baoxianzi Unknown

Indications

No indication recorded.